Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01013350 · ClinicalTrials.gov registry record
Prospective Observational Long-term Safety Registry of Multiple Sclerosis Participants Who Have Participated in Cladribine Clinical Trials
A clinical trial, sponsored by EMD Serono.
- Completed
- Registry status
- 1,161
- Enrollment target
NCT01013350: Completed study, sponsored by EMD Serono.
NCT01013350 is a clinical trial that has completed, run by EMD Serono. The registered enrollment target is 1,161 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01013350 has completed, sponsored by EMD Serono.
- COMPLETED
- Registry status
- 1,161 participants
- Enrollment target
Study Summary
Prospective Observational Long-term Safety Registry of Multiple Sclerosis Participants who Have Participated in Cladribine Clinical Trials
Primary Outcome
SADR is an adverse drug reaction that fulfils at least one of the seriousness criterion; results in death, is life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is otherwise considered as medically important. An adverse drug reaction (ADR) is a response to a medicinal product which is noxious and unintended, and which occurs at doses normally used in m
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,161 participants |
| Start Date | 2009-11-30 |
| Est. Completion | 2018-10-25 |
What the finished NCT01013350 record still lists
NCT01013350 is an observational study that tracks outcomes without assigning an intervention. Its 1,161 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT01013350 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01013350 about?
NCT01013350 is a clinical study titled "Prospective Observational Long-term Safety Registry of Multiple Sclerosis Participants Who Have Participated in Cladribine Clinical Trials". Prospective Observational Long-term Safety Registry of Multiple Sclerosis Participants who Have Participated in Cladribine Clinical Trials
What is the current status of trial NCT01013350?
This trial is currently completed. The enrollment target is 1,161 participants. The study started on 2009-11-30. Estimated completion is 2018-10-25.
Who is sponsoring clinical trial NCT01013350?
This trial is sponsored by EMD Serono, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04577599 · 1,160 participants · NA
Lung B.A.S.E.S. 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Ages 40-54
- NCT07082738 · 1,160 participants · Phase 2
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
- NCT07237048 · 1,164 participants · Phase 2
Minocycline in Stroke Study at Maimonides
- NCT07009509 · 1,166 participants · NA
Pilot Study of the YES-CAN! Program to Prevent Youth Nicotine Vaping
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI